AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

New Advances in Rosacea and Seborrheic Dermatitis

Description

The presentation covers recent advancements in understanding and treating seborrheic dermatitis (Seb Derm) and rosacea, emphasizing the need for improved treatment approaches due to their commonality and impact on quality of life. Seb Derm, characterized by inflammation in areas with numerous sebaceous glands, is often underdiagnosed, with a prevalence that could reach 10%. Major treatments currently rely on topical antifungals and steroids, which can exacerbate rosacea. The recent FDA approval of rhoflumilast 0.3% foam offers a promising new option, showing significant efficacy with low adverse effects. Meanwhile, ongoing research aims to clarify the disease's pathophysiology, spotlighting the role of immune responses and skin barrier dysfunction. Rosacea presents as a chronic inflammatory condition with varied clinical phenotypes, also suffering from underdiagnosis, particularly in skin of color. While some treatments exist, they often target microbial dysregulation without addressing underlying causes. Advances in treatment may come from understanding the complex inflammatory mechanisms driving rosacea, including TH-1 and TH-17 cell involvement and neurogenic inflammation. Future research must focus on identifying disease biomarkers and refining therapeutic strategies, recognizing the systemic implications of these skin conditions and striving to enhance patient management.

View more

Conclusions

  • Seborrheic dermatitis is one of the most common inflammatory skin diseases, particularly prevalent in patients of color.
  • New insights into the pathophysiology of seborrheic dermatitis include Th17 polarization with Th1 and Th22 upregulation and a notable lack of Th2 dysregulation.
  • Seborrheic dermatitis presents with barrier dysfunction that differs from that observed in atopic dermatitis.
  • The role of Malassezia in seborrheic dermatitis is still unclear and requires further study.
  • Roflumilast 0.3% foam has been recently approved as a safe and effective treatment for seborrheic dermatitis.
  • Investigator-initiated studies are exploring new treatment options such as topical ruxolitinib, PDE4 inhibitors, and IL-12/23 targeting therapies.
  • Rosacea is characterized by increased Th1 and Th17 cell activity and presents with varied clinical features affecting quality of life.
  • There is a need for personalized treatment approaches for rosacea due to its complexity and varied endotypes.
  • Both rosacea and seborrheic dermatitis share an association, impacting potential treatment strategies for affected patients.
  • Adalsteinsson et al., An update on the microbiology, immunology and genetics of seborrheic dermatitis. Exp Dermatol. 2020 May;29(5):481-489.
  • Gupta et al., Topical Treatment of Facial Seborrheic Dermatitis: A Systematic Review. Am J Clin Dermatol. 2017 Apr;18(2):193-213.
  • Tucker et al. Seborrheic Dermatitis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-
  • Veraldi et al. Seborrheic dermatitis and anti-COVID-19 mask. J Cosmet Dermatol. 2020 Oct;19(10):2464-2465.
  • Naldi et al., Seborrhoeic dermatitis of the scalp. BMJ Clin Evid. 2015 May 27;2015:1713.
  • Davis et al., Top dermatologic conditions in patients of color: an analysis of nationally representative data. J Drugs Dermatol. 2012 Apr;11(4):466-73.
  • Jackson et al., Unmet needs for patients with seborrheic dermatitis. J Am Acad Dermatol. 2022 Dec 17;S0190-9622.
  • Ghalili et al. IL-12/23-targeting in seborrheic dermatitis patients leads to long-lasting response. Arch Dermatol Res. 2023 Dec;315(10):2937-2940.
  • Blauvelt et al., Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a phase 3 trial: Assessment of pruritus. Presented at AAD 2023
  • Elewski B., An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face. Clin Dermatol. 2009 Nov-Dec;27(6 Suppl):S48-53.
  • van Zuuren et al. Rosacea: New Concepts in Classification and Treatment. Am J Clin Dermatol. 2021 Jul;22(4):457-465.
  • Huynh et al., Burden of Disease: The Psychosocial Impact of Rosacea on a Patient's Quality of Life. Am Health Drug Benefits. 2013 Jul;6(6):348-54.
  • Thiboutot et al., Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2020 Jun;82(6):1501-1510.
  • Gether et al., Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol. 2018 Aug;179(2):282-289.
  • Buddenkotte et al., Recent advances in understanding and managing rosacea. F1000Research 2018, 7:1885.
  • Wang et al., Multi-Transcriptomic Analysis and Experimental Validation Implicate a Central Role of STAT3 in Skin Barrier Dysfunction Induced Aggravation of Rosacea. Inflamm Res. 2022 Mar 31;15:2141-2156.
  • Hayran Y et al., Serum IL-17 levels in patients with rosacea. J Cosmet Dermatol. 2022 Mar;21(3):1147-1153.